tag

Near-Patient Testing: The Advantages of C-Reactive Protein in Hematological Testing

C-reactive protein (CRP) is an acute-phase protein that has long been recognized as a marker of systemic inflammation. CRP measurement can complement a range of diagnostic markers to monitor infection and direct treatment. However, as economic rationalization...

An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes

CHICAGO--(BUSINESS WIRE)--Jun 25, 2007 - New data from aninvestigational study released at the American Diabetes Association(ADA) 67th Annual Scientific Sessions showed that initialcombination therapy with Januvia(TM) (sitagliptin) and metformindemonstrated significant improvement in markers of beta cellfunction in patients with type 2 diabetes. Pancreatic islet betacell function determines...

Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Association's Annual Meeting

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun 25, 2007 - ElixirPharmaceuticals, Inc., today announced the presentation of two setsof preclinical data demonstrating that ghrelin antagonism may be apotential method for future treatment of a range of metabolicdisorders. These data demonstrated a variety of beneficialmetabolic effects, notably decreasing body weight, improvements inblood glucose and i...

Elixir Pharmaceuticals Presents Additional Preclinical Data Demonstrating the Potential of Ghrelin Antagonism to Regulate Metabolism, Body Weight and Glycemic Control

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun 5, 2007 - ElixirPharmaceuticals, Inc., announced today new preclinical dataconfirming ghrelin antagonism as a potential method for regulatingmetabolism, decreasing body weight and managing blood glucose. Thedata were presented in poster sessions during ENDO 07, TheEndocrine Society's 89th Annual Meeting, being held in Toronto,Canada. Elixir is focused...

Study Shows Advantages of Complete Phase Ib Trial Over Separate Phase I Trials

HOUSTON, June 04, 2007 /PRNewswire/ -- A nationally renownedcancer researcher affiliated with the US Oncology Research Networkpresented a novel study design concept called a Complete Phase Ibclinical trial as a method to accelerate new agent development.Studies utilizing this design are currently being conducted throughthe network's innovative Translational Oncology Program (TOP). TOPis...

Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III Melanoma Demonstrated Significant and Sustained Impact on Relapse-Free Survival

CHICAGO – June 2, 2007 – Long-term treatment withpegylated interferon alfa-2b in stage III melanoma had asignificant and sustained impact on relapse-free survival (RFS),according to the results of the largest adjuvant trial everconducted in patients with stage III melanoma. Results of the PhaseIII study, led by...

Surfaxin (Lucinactant) Long-Term Survival Advantage vs. Comparators Published in Pediatrics

WARRINGTON, Pa., May 31, 2007 (PRIME NEWSWIRE) -- DiscoveryLaboratories, Inc. (Nasdaq:DSCO) announces publication of theone-year follow-up results from its SELECT and STAR Phase 3clinical trials for Surfaxin(r), in Pediatrics, the premier medicaljournal for pediatric healthcare practitioners. The long-term datafrom the SELECT and STAR trials concluded that Surfaxindemonstrated a statisti...

Introgen and Clinical Collaborators to Report New Results with Advanced-Stage Cancer Therapies at Upcoming Medical Meetings

AUSTIN, Texas--(BUSINESS WIRE)--May 29, 2007 - IntrogenTherapeutics, Inc. (NASDAQ:INGN) and the Company's clinicalcollaborators will report updated Phase 2 clinical trial resultsfor its lead cancer therapy product candidates at the upcomingannual meetings of The American Society of Clinical Oncology (ASCO)in Chicago and the American Society of Gene Therapy (ASGT) inSeattle. "We have a st...

FDA MedWatch: Avastin (bevacizumab) and Formation of Tracheoesophageal Fistula in a Recent Clinical Study in Patients with Limited-stage Small Cell Lung Cancer

ROCKVILLE, Md., April 21, 2007-Genentech and FDA notifiedhealthcare professionals of important new safety informationregarding tracheoesophageal (TE) fistula formation in a recentclinical study in patients with limited-stage small cell lungcancer (SCLC). This multicenter, non-randomized, single-arm phaseII clinical trial study combined chemotherapy and radiation plusAvastin. There have b...

Benicar HCT Reductions in Seated Systolic Blood Pressure for Stage 2 Patients Compared With Amlodipine + Benazepril

Comparison of BENICAR HCT 40/12.5 and 40/25 mg/day and Amlodipine +Benazepril 5/20 and 10/20 mg/day Presented at American Society ofHypertension Twenty-Second Annual Scientific Meeting PARSIPPANY, N.J., May 21, 2007 /PRNewswire/ -- New datapresented today at the American Society of Hypertension'sTwenty-Second Annual Scientific Meeting (ASH 2007) in Chicagodemonstrated that the fixed-dose...

Affymax Announces Phase 2 Clinical Trial Results of Once-Per-Month Hematide for the Treatment of Anemia in Patients with Early- and End-Stage Chronic Kidney Disease

PALO ALTO, Calif.--(BUSINESS WIRE)--Apr 23, 2007 - Affymax, Inc.(Nasdaq:AFFY) today announced results to date from two separatePhase 2 clinical trials of Hematide(TM) in dialysis andnon-dialysis chronic kidney disease (CKD) patients. The data showedthat in treatment naive, non-dialysis patients Hematide couldcorrect anemia when administered monthly at an appropriate dose.Similarly, the data...

Curis Announces Hedgehog and Wnt Antagonist Data Presentation at AACR

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr 17, 2007 - Curis, Inc.(NASDAQ:CRIS), a drug development company focused on novel targetedmedicines primarily for cancer treatment, today announced that itsdata was included in two presentations at the 98th Annual Meetingof the American Association for Cancer Research (AACR). At AACR, Curis also disclosed that its April 2005 discoverycollaboration agr...

AEterna Zentaris Discloses In Vivo Data for its GHRH Antagonist JMR-132 at the AACR Annual Meeting in Los Angeles

JMR-132 could provide a new therapeutic approach for the treatmentof early and metastatic breast cancer QUEBEC CITY, April 17, 2007 /PRNewswire-FirstCall/ - AEternaZentaris Inc. , a global, pure play biopharmaceutical companyfocused on endocrine therapy and oncology, today presented anabstract outlining in vivo data for its growth hormone-releasinghormone (GHRH) antagonist JMR-132 in brea...

AEterna Zentaris To Present First In Vitro Data for PI3K Inhibitors and In Vivo Results for a GHRH Antagonist at the AACR Annual Meeting in Los Angeles

QUEBEC CITY, April 13, 2007 /PRNewswire-FirstCall/ - AEternaZentaris Inc. , a global, pure play biopharmaceutical companyfocused on endocrine therapy and oncology, today announced that itwill present two abstracts outlining first in vitro data on itsPI3K inhibitors as well as in vivo data on its GHRH antagonist,JMR-132, which both may potentially provide new therapeuticapproaches for the...

ECOG Phase III Newly Diagnosed Multiple Myeloma Trial (E4A03) Reports Lenalidomide Plus Low-Dose Dexamethasone Suggests Survival Advantage for Patients with Multiple Myeloma

SUMMIT, N.J., April 04, 2007 /PRNewswire-FirstCall/ -- CelgeneCorporation announced that the Eastern Cooperative Oncology Group(ECOG) has reported that its Data Monitoring Committee's (DMC)review of preliminary results from a large, randomized clinicaltrial for patients with newly diagnosed multiple myeloma has foundthat the use of a low dose of dexamethasone (Decadron) incombination wit...

Portola Pharmaceuticals Presents Positive Phase I Data of Its ADP Receptor Antagonist at the American College of Cardiology

NEW ORLEANS, March 28, 2007 /PRNewswire/ -- PortolaPharmaceuticals, Inc. presented Phase I data of its ADP receptorantagonist at the of Cardiology's (ACC) 56th Annual ScientificSession this week. Portola's reversible antiplatelet compound,PRT060128, appeared safe and well-tolerated in this study andachieved high-level platelet inhibition. Portola presented the data in a poster sess...

Schering-Plough Announces Presentation of Phase II Trial Results for Novel Oral Thrombin Receptor Antagonist at the 2007 Annual Meeting of The American College of Cardiology/i2 Summit

KENILWORTH, N.J., March 12, 2007 /PRNewswire-FirstCall/ --Schering-Plough Corporation announced today that results of thePhase II trial of its novel oral thrombin receptor antagonist (TRA)SCH 530348 will be presented at the 2007 annual Scientific Sessionsof the of Cardiology (ACC.07)/Innovation in Intervention (i2)Summit, March 24-27 in New Orleans. The Phase II trial, referred toas the...

Chemokine Therapeutics Announces Preliminary Results of CTCE-9908 Phase Ib/II Clinical Trial in Late Stage Cancer Patients

TSX: CTI OTCBB: CHKT VANCOUVER, March 12, 2007 /PRNewswire-FirstCall/ - ChemokineTherapeutics Corp. ("Chemokine Therapeutics" or the "Company") , abiotechnology company developing chemokine-based therapies to treatcancer, blood disorders, and vascular disease today announcedpositive preliminary data and the successful completion of thedose-escalation portion of its Phase Ib/II clinical tr...

Weight Management is Not Enough for Cannabinoid Type 1 (CB1) Receptor Antagonists to Become a Commercial Success

Huge clinical development program of first-in-class CB1antagonist rimonabant to show benefits beyond weight reduction andavoid image as life-style drug BARCELONA, Spain | March 08, 2007 | The Business Intelligencefirm La Merie S.L. reported today that Sanofi-Aventis’first-in-class CB1 antagonist Acomplia (rimonabant) has at leastfive competitors in clinical stages up to phase...